Adding oral semaglutide (Rybelsus) as a bridge
The DiGeorge syndrome , also called velocardiofacial or 22q11.2 deletion syndrome (22q11.2DS), is caused by a hemizygous microdeletion (1.53 Mb) on chromosome 22 The prevalence rate of this condition is ~1 in 4000 [356]
PMID: 30,142,545
This is a nutritional issue rather than a direct pharmacological effect on the mammary glands
The packaging opens and closes well, seems secure, and is compact compared to other collagen and protein powder containers. Needed received a 1 out of 5 stars for the vague instructions, as Mindy was unclear what taking throughout the day as needed truly meant
Treatment stage What may be common What deserves attention Week 1 Nausea, fullness, reduced appetite, bloating, indigestion, diarrhea, constipation, fatigue Repeated vomiting, severe pain, inability to stay hydrated Weeks 2 to 4 Early symptoms may settle, persist, or fluctuate Symptoms interfering with eating, drinking, or daily function Weeks 5 to 8 Symptoms may reappear after clinician-directed dose escalation A significant return or worsening of gastrointestinal symptoms Months 2 to 3 Some patients tolerate treatment more comfortably
